LONDON (AP) — Britain's communications regulator says it's investigating China's state TV channel over a complaint about fairness and privacy.
Drug maker to spend $100M expanding Montana facility
HAMILTON, Mont. (AP) — Drugmaker GlaxoSmithKline has announced $100 million of new investment in its manufacturing site in Montana.
British-based GSK said in a statement released Wednesday...
LONDON (AP) — The World Health Organization says Malawi has become the first country to begin immunizing children against malaria, using the only licensed vaccine to protect against the...
FDA OKs 1st generic version of popular Advair asthma inhaler
The first generic version of the popular Advair asthma inhaler has been approved by U.S. regulators.
The Food and Drug Administration on Wednesday approved Mylan's version in three strengths for ages 4 and up.
The inhalers are used twice daily to keep airways open and prevent flare-ups of wheezing, shortness of breath and other symptoms of asthma or chronic obstructive pulmonary disease. About 42 million Americans have those conditions.
GlaxoSmithKline and General Mills climb while FedEx drops
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday:
FedEx Corp., down $22.50 to $162.51
The shipping company said international shipping dropped in the last quarter.
GlaxoSmithKline PLC, up 31 cents to $37.40
The drug company will combine its consumer product division with that of competitor Pfizer.
Micron Technology Inc., down $2.70 to $31.41
The chipmaker reported weak sales and gave disappointing forecasts for the year, saying demand is weakening.
Glaxo, Pfizer to merge consumer health care divisions
Drugmakers GlaxoSmithKline and Pfizer plan to merge their consumer health businesses into what will be the world leader in sales of nonprescription medicines such as pain relievers, vitamins and cold remedies.
The new joint venture would have with combined annual sales of $12.7 billion (9.8 billion pounds).
British-based GSK will own 68 percent of the venture, and New York-based Pfizer, the biggest U.S. drugmaker, will own the remaining 32 percent stake.
Tribune Media, Amazon rise; GlaxoSmithKline, Discovery fall
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday:
Tribune Media Co., up $4.72 to $44.98
The TV station owner agreed to be acquired by Nexstar, four months after a bid from Sinclair Broadcast Group collapsed.
GlaxoSmithKline PLC, down $3.26 to $38.61
The drugmaker agreed to acquire Tesaro, which makes the ovarian cancer treatment Zejula.
GlaxoSmithKline to spend $5.1B on cancer drugmaker Tesaro
Shares of Tesaro soared Monday after GlaxoSmithKline said it would pay about $5.1 billion in cash to buy the cancer drugmaker.
Glaxo plans to pay $75 per share for Tesaro, which makes the ovarian cancer treatment Zejula. That represents a premium of more than 60 percent to the stock's $46.38 closing price Friday. The total deal price includes Tesaro's net debt.
Glaxo CEO Emma Walmsley said in a statement that the deal will accelerate growth of the British drugmaker's oncology business.
British man seeks China state TV ban for forced confession
LONDON (AP) — A British corporate investigator filed a complaint Friday to U.K. regulators about China's state TV channel, saying its British license should be revoked because it aired his forced confession when he was imprisoned in China.
Peter Humphrey submitted the complaint against China Central Television and its international division, China Global Television, for violating British broadcasting rules.
Chinese scientist pleads guilty in plot to steal GSK secrets
PHILADELPHIA (AP) — A Chinese scientist has pleaded guilty to conspiring to steal biopharmaceutical trade secrets from GlaxoSmithKline in what prosecutors said was a scheme to set up companies in China to market them.
Tao Li pleaded guilty Friday in federal court to a single conspiracy count. The change of plea comes two weeks after Yu Xue, a high-ranking researcher who worked at GlaxoSmithKline's suburban Philadelphia research facility, also pleaded guilty to a conspiracy charge.
GlaxoSmithKline to cut 650 US jobs, reinvest in R & D
RALEIGH, N.C. (AP) — Pharmaceutical company GlaxoSmithKline will cut 650 jobs across the United States.
The News & Observer reports the United Kingdom-based company notified the North Carolina Department of Commerce on Wednesday that it will cut 100 jobs at its Research Triangle Park office, and 450 field sales jobs across the country. GlaxoSmithKline is also cutting 100 positions at its Philadelphia office.
Researcher admits plot to steal GSK secrets to sell in China
PHILADELPHIA (AP) — A cancer researcher pleaded guilty Friday to conspiring to steal biopharmaceutical trade secrets from GlaxoSmithKline in what prosecutors said was a scheme that involved plans to set up companies in China to market them.
Yu Xue entered a guilty plea in federal court to a single conspiracy count. The government dropped more than two dozen other pending counts against the researcher.
BOISE, Idaho (AP) — Some Idaho residents may have to wait until next year to get the new shingles vaccine.
The Idaho Statesman reports the vaccine, Shingrix, has been on high demand nationwide since it was released in February. That's caused a lack of inventory for many pharmacies.
U.S. regulators Friday approved a simpler, one-dose treatment to prevent relapses of malaria.
Standard treatment now takes two weeks and studies show many patients don't finish taking every dose.
Malaria is caused by parasites that are spread to people through mosquito bites. Antimalarial drugs can cure the initial infection but parasites can get into the liver, hide in a dormant form, and cause recurrences months or years later. A second drug is used to stop relapses.
Stronger pound weighs on revenues at drugmaker GSK
LONDON (AP) — Pharmaceutical and consumer goods maker GlaxoSmithKline says first-quarter revenue dropped 2 percent as a stronger pound offset encouraging sales of a new shingles treatment.
Avara acquires former GlaxoSmithKline pharmaceutical manufacturing plant north of Aiken
An international company headquartered in Connecticut is the new owner of a consumer health care manufacturing facility north of Aiken.
Avara Pharmaceutical Services announced in a press release issued earlier this month that it had completed the purchase of the 250,000-square-foot plant from another international firm, GlaxoSmithKline, which is based in England.
CHICAGO (AP) — Two popular stop-smoking drugs are as safe for the heart as nicotine patches and dummy pills, according to research requested by U.S. and European regulators.
The results come from an extension of a big study of Chantix and Zyban that earlier found no increased risks for severe psychiatric problems including suicidal behavior. Those findings were reported in 2016.
- Connecticut PostShingles vaccine shortage in ConnecticutDecember 11, 2018
- Philly.comScientist admits receiving trade secrets from GlaxoSmithKline to aid company in ChinaSeptember 15, 2018
- Philly.comChinese American scientist admits plot to steal GlaxoSmithKline's trade secrets for firm in ChinaAugust 31, 2018
- Tribune-ReviewShaler North Hills library hosts science programAugust 16, 2018
GENEVA (AP) — Swiss pharmaceutical firm Novartis is selling its stake in a consumer health care joint venture with GlaxoSmithKline to the British company for $13 billion.
The joint venture was formed in 2015 and Novartis holds a 36.5-percent stake. Novartis CEO Vas Narasimhan said in a statement Tuesday that it "is progressing well," but "the time is right for Novartis to divest a non-core asset at an attractive price."
The former chief executive at pharmaceutical giant GlaxoSmithKline, Andrew Witty, has been named chief executive at Optum, the huge and still fast-growing health care services business of UnitedHealth Group.
Witty will step down immediately from the UnitedHealth Group board of directors and succeed Larry Renfro as Optums leader. Renfro will become managing partner for a series of domestic and international funds called Optum Ventures.
Loretta V. Marsh, a retired medical technologist, died on Thursday, Feb. 1, 2018. She was 69.
She was born on Feb. 24, 1948. She was the second eldest of seven children born to the late Dorothy J. Statesman Marsh and the late Laurie E. Marsh Sr.
GSK sinks to Q4 loss on US tax code changes
LONDON (AP) — Drugmaker GlaxoSmithKline sank to a fourth-quarter loss of 546 million pounds ($758 million) from a profit of 257 million pounds a year earlier, as it dealt with U.S. tax changes.
The deterioration came despite a 1 percent rise in sales to 7.6 billion pounds.
On Oct. 26, 2017, a new shingles vaccine was officially approved by the FDA. The brand name is Shingrix. (You tell me where they came up with that moniker.) The official Advisory Committee on Immunization Practices (ACIP) of the CDC voted Oct. 25 to recommend this new product over Zostavax, made by the drug company Merck, which has been around since 2006. Shingrix is sold by the GlaxoSmithKline drug company. It will be released for general use in 1-2 months.
Bridging the digital divide: Community Empowerment Fund uses tech ‘one-on-one’ to build better lives
Use Salesforce and all its software power to bridge the digital divide? Absolutely.
Just ask the Triangle-based Community Empowerment Fund.
How to bridge the technology divide between the "haves" and the "have nots" has vexed technology thought leaders, executives and millions of others who seek ways to improve lives since the Internet exploded more than two decades ago.
GlaxoSmithKline's promising new blood cancer drug has received another big boost, this time being granted "breakthrough" status by the Food and Drug Administration.
The FDA and GSK announced the designation Thursday.
Just a month ago, a similar status was awarded to the drug candidate by European drug authorities as well as an "orphan" designation.
Panel recommends new, better shingles shot over old version
NEW YORK (AP) — A federal panel recommended Wednesday that older people already vaccinated for shingles get a new, better shot.
The advisory group said the just-approved vaccine made by GlaxoSmithKline works better at preventing shingles and may last longer than the one that's been sold in the U.S. since 2006.
Correction: FDA-Shingles Vaccine story
In a story Oct. 20 about U.S. approval of GlaxoSmithKline's shingles vaccine, The Associated Press reported erroneously that the drugmaker is testing its new vaccine against an older one sold by Merck & Co. The study is being conducted by University of Colorado researchers; Glaxo is providing its vaccine for the research.
A corrected version of the story is below:
FDA approves better vaccine against painful shingles virus
- Globe NewswireStreamSets Showcases Major Attractions at DataOps Summit 2019May 23, 2019
- Globe NewswireFormer Mars Petcare Executive Kevin Cole Joins True Leaf as PresidentMay 7, 2019
- Business WireVectura Wins US GSK Patent Litigation and Awarded $89.7Million in Damages by Trial JuryMay 4, 2019
- Business WirePhase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary EndpointMay 2, 2019
FDA OKs Glaxo’s inhaler, first one to combine 3 medicines
TRENTON, N.J. (AP) — The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis.
The FDA late Monday approved sales of Trelegy Ellipta, developed jointly by GlaxoSmithKline PLC and Innoviva Inc. It contains three widely used types of medicine to prevent — rather than treat —flare-ups of the life-threatening breathing disorders.
GlaxoSmithKline joined two other private donors, AECOM and Savannah River Nuclear Solutions, on Friday in support of Aiken County Public Schools’ implementation of the National Math and Science Initiative College Readiness Program at South Aiken and North Augusta high schools.
GSK warns of impact from generic drugs after solid Q1
LONDON (AP) — GlaxoSmithKline says new products helped first-quarter sales rise 17 percent from the year before but warned that competition from generic drugs may weigh on earnings later this year.
London-based GSK said Wednesday that its sales jumped to 7.38 billion pounds ($9.47 billion) from 6.23 billion pounds, ahead of analysts' expectations for a rise to 7.3 billion pounds.
And net income more than tripled to 1.05 billion pounds.
CHICAGO (AP) — A suburban Chicago woman has been awarded $3 million in a lawsuit against a pharmaceutical company she blamed for her husband's suicide.
Wendy Dolin's husband, Stewart, stepped in front of a Chicago Transit Authority train on July 15, 2010. He had been taking paroxetine, a drug for depression and anxiety.
Dolin claimed GlaxoSmithKline failed to warn her husband's doctor that the drug could increase risk of suicidal behavior.
GlaxoSmithKline is recalling almost 600,000 asthma inhalers due to potential problems with the product leaking.
The affected lot numbers are 6ZP0003, 6ZP9944 and 6ZP9848, according to CNN. The devices were recalled from hospitals, pharmacies, retailers and wholesalers in the United States.
The defect does not make the product dangerous to users, but it might not provide as many doses of the medicine as promised.
NEW YORK (AP) — Bill O'Reilly's top-rated Fox News show may be starting to feel a financial sting after allegations that he sexually harassed several women.
A dozen major advertisers, ranging from automakers Hyundai and BMW, to financial firm T. Rowe Price, insurer Allstate and drugmaker GlaxoSmithKline, have pulled their ads from "The O'Reilly Factor."
Local nonprofits sought for GSK awards
GlaxoSmithKline and The Philadelphia Foundation have issued the call for applications for the 2017 GSK IMPACT Awards.
The annual awards recognize local nonprofits that are addressing everyday health barriers in the five-county Philadelphia region.
GlaxoSmithKline says in its annual report that it will pay incoming CEO Emma Walmsley – the first woman to lead a top drug maker – some 25 percent less than the man she is replacing.
"Taking into account the fact that this is Emma's first CEO role, reductions have been made to all elements of her remuneration package in comparison to Sir Andrew's current arrangements," the report says, according to Reuters and various other media reports in the U.K., where GSK is based.
LONDON (AP) — When investigators Peter Humphrey and Yu Yingzeng were hired by pharmaceutical company GlaxoSmithKline in 2013, their job was to look into a former employee in China who, they were told, was making false allegations about the firm.
GSK warns profits to be hit by generic drugs competition
LONDON (AP) — Pharmaceutical company GlaxoSmithKline saw its sales and profits grow in the fourth quarter but warned that tougher competition from generic drugmakers could depress its earnings this year.
The London-based company said Wednesday its net income rose to 257 million pounds, from a loss of 354 million pounds a year earlier. Sales rose to 7.6 billion pounds, above both market expectations for 7.5 billion pounds and the previous year's figure of 6.3 billion pounds.
J&J to spend $30 billion on Swiss drugmaker Actelion
Johnson & Johnson will buy Swiss drugmaker Actelion in a $30 billion deal that both secures promising research and bolsters the product portfolio controlled by the U.S. health care giant.
Much of Actelion's research operation will be spun off into a separate company in which J&J will own a minority stake. The U.S. conglomerate will then buy Actelion's seven drugs that are currently on the market and two potential treatments in late-stage testing.
WADA signs agreement with Japanese drug maker
TOKYO (AP) — The World Anti-Doping Agency has signed an agreement with Japanese drug maker Astellas Pharma Inc. to help fight doping in sports.
Astellas will identify compounds it produces, including those in development, that could be abused by athletes and share the information with the agency to help find methods of detecting the substances.
The company also will cooperate with WADA to minimize risks of such substances being misused while they're still in clinical trials.
By Linda Loyd, Staff Writer
GlaxoSmithKline on Tuesday named Emma Walmsley as its new chief executive officer, the first woman to head Britain's largest drugmaker.
GSK has a major presence in the Philadelphia region.
Continue reading on Philly.com
GlaxoSmithKline picks Emma Walmsley, a female executive of its management team, to replace CEO Andrew Witty when he retires early next year.
The news was announced early Tuesday in London where the drug giant is based. It also employs several thousand people in the Triangle area in research, manufacturing and other areas.
Walmsley currently runs the company's consumer healthcare division, established as part of a deal in which GSK swapped its cancer-drug unit for Novartis's vaccine business.
GSK names Emma Walmsley as new chief executive
LONDON (AP) — Drugmaker GlaxoSmithKline says Emma Walmsley will be the company's new chief executive, replacing Andrew Witty when he retires next March.
Walmsley currently runs the company's consumer healthcare division, established as part of a deal in which GSK swapped its cancer-drug unit for Novartis's vaccine business.
She joined GSK in 2010 from L'Oreal, where she held roles in the U.K., Europe and China.
A former GlaxoSmithKline factory in Clifton has been repurposed as a warehouse and distribution center by a partnership of two North Jersey developers who are seeking a tenant for the renovated 204,000-square-foot building as investor appetite for the warehouse sector in North Jersey shows no signs of abating.
LONDON (AP) — One of Google's sister companies will team up with pharmaceuticals firm GlaxoSmithKline to develop tiny implants that can tap nerves and change their electronic signals as a way of treating chronic illnesses.
GSK and Verily Life Sciences, a subsidiary of Google parent company Alphabet, have agreed to create a new company known as Galvani Bioelectronics, which will be based in Britain, with a second research hub in South San Francisco,...
Pharmaceutical giant GSK invests in British sites
LONDON (AP) — GlaxoSmithKline is investing some 275 million pounds ($360 million) into three plants in Britain, sweeping aside concerns about growth following the country's decision to leave the European Union.
The pharmaceutical giant's chief executive Andrew Witty said Tuesday that the Britain's "competitive corporate tax system" and skilled workforce influenced the decision to invest in the manufacturing of new respiratory and large molecule biological...